Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × NPI 2358 × Thoracic × Clear all
NCT02504489 2026-05-19

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
559 enrolled 32 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07361484 2026-01-23

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

BeyondSpring Pharmaceuticals Inc.

Phase 3 Not yet recruiting
442 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡